glp 1 and pots Asda jumps on GLP-1 bandwagon with high-protein 'power pots' GLP-1 medications safe to continue
Description
K., Hong, C
The study included 67,841 patients taking semaglutide (75.6%), 15,661 taking tirzepatide (17.5%), and 6,216 taking liraglutide (6.9%)
Key Takeaways Oral formats can help more patients feel comfortable with treatment
Follow the nutritional guidance we provide
PEG modification increased the stability of protein and peptide drugs, increased the solubility, reduced the immunogenicity, prolonged the residence time in blood, reduced the protease degradation, and reduced the frequency of drug use
Its stimulant properties increase heart rate and blood pressure, making it unsuitable for individuals with cardiovascular risk factors
